The 2025 European Alliance of Associations for Rheumatology update for Behçet’s syndrome introduced 5 overarching principles and 12 organ-specific recommendations, incorporating evidence from 81 studies, including 9 randomized trials, to guide individualized treatment based on disease manifestations. The guidance highlights earlier use of biologic disease-modifying antirheumatic drugs for major organ involvement while acknowledging that many recommendations rely on limited randomized data and observational evidence, highlighting ongoing gaps in optimal treatment sequencing and long-term management.

Source: Annals of the Rheumatic Diseases